血浆趋化因子是肺结核不良治疗结局的基线预测因子
本研究在印度金奈的耐药敏感肺结核成人队列中,比较治疗前血浆趋化因子水平与不良治疗结局的关系。发现CCL2、CCL3、CCL4、CXCL8、CXCL10和CX3CL1与不良结局风险增加相关,而CXCL1与风险降低相关;验证队列中CCL3、CXCL8和CXCL10与风险增加相关。CCL3、CXCL8和CXCL10组合在区分病例与对照中表现出很高的敏感性和特异性。
要点
- 治疗前血浆CCL3、CXCL8和CXCL10升高与肺结核不良治疗结局风险增加相关。
- CCL3、CXCL8和CXCL10联合检测对预测不良结局有很高敏感性和特异性。
- CXCL1与不良治疗结局风险降低相关,提示潜在保护作用。
核心结论
- 血浆趋化因子特征可作为预测肺结核不良治疗结局的新型生物标志物。
研究设计与样本
- 测试队列纳入68例不良结局病例和136例无复发治愈对照,均为新诊断痰涂片和培养阳性的药物敏感肺结核成人。
- 验证队列纳入20例病例和40例对照,均为新诊断培养阳性的药物敏感结核成人。
主要发现
- 测试队列中,CCL2、CCL3、CCL4、CXCL8、CXCL10和CX3CL1与不良结局风险增加相关,CXCL1与风险降低相关。
- 验证队列中,CCL3、CXCL8和CXCL10与不良治疗结局风险增加相关。
- ROC分析显示CCL3、CXCL8和CXCL10组合在区分病例与对照中具有很高敏感性和特异性。
临床怎么用
- 治疗前检测血浆CCL3、CXCL8和CXCL10水平可能有助于识别肺结核不良治疗结局高危患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Plasma chemokines are biomarkers of greater disease severity, higher bacterial burden, and delayed sputum culture conversion in pulmonary tuberculosis (PTB). Whether plasma chemokines could also serve as biomarkers of unfavorable treatment outcomes in PTB is not known. METHODS: A cohort of newly diagnosed, sputum smear- and culture-positive adults with drug-sensitive PTB were recruited under the Effect of Diabetes on Tuberculosis Severity study in Chennai, India. Plasma chemokine levels measured before treatment initiation were compared between 68 cases with unfavorable outcomes (treatment failure, death, or recurrence) and 136 control individuals who had recurrence-free cure. A second validation cohort comprising newly diagnosed, culture-positive adults with drug-sensitive TB was used to measure plasma chemokine levels in 20 cases and 40 controls. RESULTS: Six chemokines (CCL2, CCL3, CCL4, CXCL8, CXCL10, and CX3CL1) were associated with increased risk, while CXCL1 was associated with decreased risk of unfavorable outcomes in unadjusted and adjusted analyses in the test cohort. Similarly, CCL3, CXCL8, and CXCL10 were associated with increased risk of unfavorable treatment outcomes in the validation cohort. Receiver operating characteristic analysis revealed that combinations of CCL3, CXCL8, and CXCL10 exhibited very high sensitivity and specificity in differentiating cases vs controls. CONCLUSIONS: Our study reveals a plasma chemokine signature that can be used as a novel biomarker for predicting adverse treatment outcomes in PTB.
引用
- Kumar NP, Moideen K, Nancy A, et al. Plasma Chemokines Are Baseline Predictors of Unfavorable Treatment Outcomes in Pulmonary Tuberculosis. Clin Infect Dis. 2021. PMID: 32766812. doi:10.1093/cid/ciaa1104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。